Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-23
2009-02-03
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S403000
Reexamination Certificate
active
07485730
ABSTRACT:
Tricyclic pyrazole derivatives of the following formula (I) having affinity for the cannabinoidergic CB1 and/or CB2 receptors:wherein:A represents a group selected from one of the following:(CH2)t—, —(CH2)—S(O)z—, or —S(O)z—(CH2)—,B is a heteroaryl, optionally substituted;R is a group selected from the following:alkyl, aryl, arylalkyl or arylalkenyl, not substituted or having from one to four substituents, equal to or different from each other;R′ is a group selected from the following:an ether group of formula —(CH2)—O—(CH2)v—R″,a ketonic group of formula —C(O)-Z′,a substituent having an hydroxyl function of formula —CH(OH)-Z′; andan amide substituent of formula —C(O)—NH-T′.
REFERENCES:
patent: 5547975 (1996-08-01), Talley et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6080745 (2000-06-01), Davey et al.
patent: 6100259 (2000-08-01), Xiang et al.
patent: 2001/0053788 (2001-12-01), Lange et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 0 656 354 (1995-06-01), None
patent: 1 230 222 (2002-08-01), None
patent: 1 230 244 (2002-08-01), None
patent: WO 01/32629 (2001-05-01), None
patent: WO 01/32663 (2001-05-01), None
patent: WO 01/32663 (2001-05-01), None
patent: WO 03/070236 (2003-08-01), None
patent: WO-03/070706 (2003-08-01), None
patent: WO-2004/104007 (2004-12-01), None
Thompson et al., Current Medicinal Chemistry, Oct. 2002, 9(19), pp. 1751-1762.
CA Registry No. 727666-49-1, entry date into the Registry file on STN is Aug. 17, 2004.
D'Alessio et al., Bioorganic & Medicinal Chemistry Letters, 15, (Mar. 1, 2005), pp. 1315-1319.
Q. Lu et al., “Expression of CB2 cannabinoid receptor mRNA in adult rat retina”,Visual Neurosci. 17, 91-95, 2000.
M. Glass, “The Role of Cannabinoids in Neurodegenerative Diseases”,Prog. Neoro-Psychopharmacol.&Biol. Psychiatri. 25, 743-765, 2001.
A. Porcella et al., “Cannabinoid receptor CB1mRNA is highly expressed in the rat ciliary body; Implications for the antiglaucoma properties of marihuana1”,Molecular Brain Research58, 240-245, 1998.
A. Porcella et al., “The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein”,European Journal of Neurosci. 12, 1-5, 2000.
M Pacheco et al., “Aminoalkylindoles: Actions on Specific G-Protein-Linked Receptors1”,J. Pharmacol. Exp. Ther. 257, 170-183, 1991.
B.R. Martin et al., “Behavioral, Biochemical, and Molecular Modeling Evaluations of Cannabinoid Analogs”,Pharmacol. Biochem. Behav. 40. 471-478, 1991.
P.B. Smith et al., “The Pharmacological Activity of Anandamide, a Putative Endogenous Cannabinoid, in Mice”,J. Pharmacol. Exp. Ther. 270, 219-227, 1994.
M. Rinaldi-Carmona et al., SR141716A, a potent and selective antagonist of the brain cannabinoid receptor,FEBS Lett., 350, 240-244, 1994.
M. Rinaldi-Carmona et al., “SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor”,J. Pharmacol. Exp. Ther. 284, 644-650, 1998.
Remington, “The Science and Practice of Pharmacy”, II, 1457, 1995.
H. Tanaka et al., “Synthesis and evaluation of novel 2-aryl-2,5,6,7-tetrahydro-3H-thieno[2′,3′:6,7]cycloheptal[1,2-c]pyridazin- ,-ones and 2-aryl-5,6-dihydrothienol[2,3-h]cinnoln-3(2H)-ones as anxiolytics”,Eur. J. Med. Chem.32, 607-615, 1997.
G.A. Pinna et al., “Synthesis and pharmacological evaluation of thienocinnolin-3-(2H)-ones, bioisosters of antihypertensive and antithrombotic benzo(h)cinnolinones”,Eur. J. Med. Chem. 29, 447-454, 1994.
G.A. Pinna et al., “Addition Reactions of Acetylenic Esters Upon 1-(2-Thienyl)- and 1-(3-Thienyl)-Ethanone Oximes and Upon 6,7-Dihydrobenzo(b)Thiophen-4(5H)-One and 5,6-Dihydrobenzo[b]Thiophen-7(4H)One Oximes, Formation of 2-(Thienyl)-Pyrroles and 4,5-Dihydro-1H-Thieno[g]Indoles”,British Library—Paper E/2/06335B, 1279-1296, 1992.
G.A. Pinna et al.,J. Chem. Res., 1273-1281, 1993.
W.M. Rawls et al., “CB1Receptors in the Preoptic Anterior Hypothalamus Regulate WIN 55212-2 [(4,5-Dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-Induced Hypothernia”,J. Pharmacol. Exp. Ther. 303, 395-402, 2002.
R.G. Pertwee, “Further evidence for the presence of cannabinoid CB1receptors in guinea-pig small intestine”, Br. J. Pharmacol. 118, 2199-2205—1996.
G. Colombo et al., “Cannabinoid modulation of intestinal propulsion in mice”, Eur. J. Pharmacol. 344, 67-69, 1998.
M. A. Casu et al., “Differential distribution of functional cannabinoid CB1receptors in the mouse gasstroenteric tract”,Eur. J. Pharmacol. 459, 97-105, 2003.
Y. Nagakura et al., “Compounds possessing 5-HT3receptor antagonistic activity inhibit intestinal propulsion in mice”,Eur. J. Pharmacol. 311, 67-72, 1996.
European Search Report, EP 0501 0832, Aug. 17, 2005.
Mussinu & Co., “Tricyclic Pyrazoles. Part 1. Synthesis and Biological Evaluation of Novel 1,4-Dihydroindeno[1,2-c] pyrazol-based Ligands for CB1and CB2Cannabinoid Receptors”,Biorganic&Med. Chem. 11, 251-263, 2003.
Franjo Grotenhermen, “Pharmacology of Cannabinoids”, Neuroendocrinology Letters, vol. 25, Nos. 1-2, pp. 14-23 (2004).
M.R. Pazos, et al., “Role of the endocannabinoid system in Alzheimer's disease: New perspectives”, Life Sciences, 75, pp. 1907-1915 (2004).
Leo E. Hollister, “Health Aspects of Cannabis”, Pharmacological Reviews, vol. 38, No. 1, pp. 1-20 (1986).
Philip W. Wirth, et al., “Anti-Inflammatory Properties of Cannabichromene”, Life Science, vol. 26, pp. 1991-1995, (1980).
Murielle Rinaldi-Carmona et al., “SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor”, The Journal of pharmacological and experimental therapeutics, vol. 284, No. 2, pp. 644-650 (1998).
Mussinu et al. (2003) Tricyclic Pyrazoles. Part 1: Synthesis and biological evaluation of novel 1,4-Dihydroindeno[1,2-c]pyrazole-based ligands for CB1and CB2cannabinoid receptors. Bioorganic & Medicinal Chemistry 11:251-263.
Lazzari Paolo
Murineddu Gabriele
Pinna Gerard Aime
Ruiu Stefania
Knobbe Martens Olson & Bear LLP
Neuroscienze Pharmaness S.C. A R.L.
Stockton Laura L.
LandOfFree
Pharmaceutical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4059732